Madrigal Pharmaceuticals Q4 Earnings Call Highlights

Management said patient growth continued through the fourth quarter. The company reported ending the quarter with more than 36,250 patients on Rezdiffra, up from more than 29,500 at the end of the third quarter. Sibold noted the patient figure reflects the net of new starts and discontinuations.Sibold attributed the commercial performance to building the market “from scratch,” including prescriber education, establishing care pathways, expanding prescriber breadth and depth, and contracting for access. He a ...